Current limitations & potential innovations in developing IND-enabling rAAV- & lentivirus-based gene therapy drug products

Abi Pinchbeck, Assistant Editor, Cell & Gene Therapy Insights, speaks to Rahul Kaushik, viral vector-based gene therapy expert, who compares recombinant AAVs and lentiviral vectors for in vivo and ex vivo gene therapy and discusses novel analytical tools in the space, including those to overcome purity analysis, immunogenicity toxicity, and re-dosing challenges

Please enter your email to access content Read now